Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

• US 9,186,346 B2
• Filed: 02/04/2014
• Issued: 11/17/2015
• Est. Priority Date: 02/04/2013
• Status: Active Grant

• Current Assignee: Sanofi
• Original Assignee: Sanofi
• Inventors: Weitz, Dietmar, Menguy-Vacheron, Francoise, Clot, Pierre-Francois, Turpault, Sandrine
• Primary Examiner(s): TRAN, MY CHAU T
• Application Number:
  US14/172,082
• Publication Number:
  US 20140256758A1
• Time in Patent Office: 651 Days
• Field of Search: 514/256, 514/275, 514/521, 514/557, 514/627
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system

Abstract

This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3).

Claims

1. A method for treating multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction in a patient having multiple sclerosis, wherein rosuvastatin is co-administered with teriflunomide, comprising administering to the patient about 7 or 14 mg of teriflunomide daily, and administering to the patient rosuvastatin which is at the amount of about 50% of the normal dose of rosuvastatin.

2. The method according to claim 1, wherein the patient has relapsing forms of multiple sclerosis.

3. The method according to claim 1, wherein rosuvastatin is co-administered with teriflunomide at the same time.

4. The method according to claim 2, wherein rosuvastatin is co-administered with teriflunomide at the same time.

5. A method for treating multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction in a patient having multiple sclerosis, wherein rosuvastatin is co-administered with teriflunomide, comprising administering to the patient about 7 or 14 mg of teriflunomide daily, and administering to the patient rosuvastatin at a dose that does not exceed 10 mg once daily.

6. The method according to claim 5, wherein the patient has relapsing forms of multiple sclerosis.

7. The method according to claim 5, wherein rosuvastatin is co-administered with teriflunomide at the same time.

8. The method according to claim 6, wherein rosuvastatin is co-administered with teriflunomide at the same time.